Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150040/S024

VISUMAX 800 Femtosecond Laser

Carl Zeiss Meditec, Inc. · Decision date May 26, 2026

FDA DECISIONP150040/S024

What did the FDA approve?

FDA records P150040/S024 as a supplement to PMA P150040, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 26, 2026.

FDA approval order statement

design changes to the laser sources to address temperature-induced laser beam drift
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ophthalmic
Decision date
May 26, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P150040/S024
Regulatory pathway
PMA supplement
Product code
OTL
Decision code
APPR
Decision date
May 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Femtosecond laser system for refractive correction.

Product code
OTL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P150040/S023 · Related supplement

    VISUMAX 800 Femtosecond Laser

  2. P150040/S024 received

    Application receipt date recorded by FDA.

  3. P150040/S025 · Related supplement

    Visumax Femtosecond Laser

  4. P150040/S024 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P150040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150040

Product / regulatory recordCompanyPathwayDecision dateSource
Carl Zeiss Meditec, Inc.PMA supplementAug 21, 2025FDA
Carl Zeiss Meditec, Inc.PMA supplementOct 16, 2025FDA
Carl Zeiss Meditec, Inc.PMA supplementDec 18, 2025FDA
Carl Zeiss Meditec, Inc.PMA supplementMay 20, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Carl Zeiss Meditec, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5160 Hacienda Dr., Dublin, CA, 94568

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records